Phase IIa trial to evaluate different delivery schedules of recombinant human interleukin-7 in combination with oral capecitabine in the second-line treatment of metastatic breast cancer

Trial Profile

Phase IIa trial to evaluate different delivery schedules of recombinant human interleukin-7 in combination with oral capecitabine in the second-line treatment of metastatic breast cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Interleukin-7 (Primary) ; Capecitabine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms ELYPSE-7
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Jun 2014 New source integrated into profile.
    • 26 Jun 2014 Planned End Date changed to 1 Jun 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top